Predicted choice and acceptability of regimens for tuberculosis preventive treatment among people living with HIV in Uganda – A discrete choice experiment

Bibliographic Data

ID24144075
AuthorsHélène E Aschmann (0000-0003-1234-4321, University of California, San Francisco), Allan Musinguzi (0000-0001-9941-6433, Infectious Diseases Research Collaboration), Jillian L Kadota (0000-0003-4568-8681, University of California, San Francisco), Catherine Namale (0000-0001-9830-2266, Uganda Tuberculosis Implementation Research Consortium), Juliet Kakeeto (0009-0001-8942-4816, Uganda Tuberculosis Implementation Research Consortium), Jane Nakimuli (0009-0001-2701-2330, Infectious Diseases Research Collaboration), Lydia Akello (0009-0009-4013-9692, Infectious Diseases Research Collaboration), Fred Welishe (Infectious Diseases Research Collaboration), Anne Nakitende (0000-0001-8198-6681, Infectious Diseases Research Collaboration), Christopher Berger (University of California, San Francisco), David Dowdy (0000-0003-0481-7475, Uganda Tuberculosis Implementation Research Consortium), Adithya Cattamanchi (0000-0002-6553-2601, University of California, San Francisco), Fred C Semitala (0000-0002-0624-7640, Infectious Diseases Research Collaboration), Andrew D Kerkhoff (0000-0002-5023-6658, University of California, San Francisco)
EditorsGraeme Hoddinott (0000-0001-5915-8126, The University of Sydney)
Year2026
Volume6
Issue9
Pagese0005630
Publication date2026-09-10
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenuePLOS Global Public Health (JOURNAL)
Journal identifiersISSN: 2767-3375 • E-ISSN: 2767-3375
PublisherPublic Library of Science (PLoS) (PUBLISHER)
DOI10.1371/journal.pgph.0005630
LanguageEN
References cited26

Little is known about people living with HIV’s preferences for different tuberculosis preventive treatment (TPT) regimens, or the conditions under which they would accept treatment. Actionable evidence regarding preference for TPT is needed to inform policy and the development of novel TPT regimens. Adults engaged in care at an HIV clinic in Kampala, Uganda, completed a discrete choice experiment survey with nine random choice tasks. In each task, participants first chose between two hypothetical TPT regimens with differing treatment features (number of pills, frequency, duration, adjusted antiretroviral dosage, and side effects). Second, they answered if they would accept the selected treatment, versus taking no treatment. We simulated predicted TPT regimen choice based on hierarchical Bayesian estimation of individual preference weights. Among 400 participants, 394 gave high-quality answers and were included (median age 44, 71.8% female, 91.4% previously received TPT). Across nine tasks, 60.2% (237/394) accepted all selected TPT regimens, 39.3% (155/394) accepted some regimens, and 0.5% (2/394) accepted none. Choice simulations showed that if only 6 months of daily isoniazid (6H) was available, 11.9% of participants were predicted to prefer no TPT. However, offering a 4-pill, fixed-dose combination 3HP regimen in addition to 6H increased the acceptability from 88.1% to 98.8% (predicted choice of 3HP 94.5%, 6H 4.4%, no TPT 1.2%). Choice simulations showed that 10 pills per dose and antiretroviral dosage adjustment had the largest effects on reducing the acceptability of regimens. While adults living with HIV in Uganda demonstrate a high willingness to accept different TPT regimens, offering regimens with preferred features, such as 3HP as a fixed-dose combination, could drive TPT acceptance and uptake from high to nearly universal.